

1 CLAIMS

- 2
- 3 1. Use of a test for detecting the genetic basis of
- 4 Gilbert's Syndrome in a method to improve the
- 5 efficacy of drug trials, the method comprising
- 6 screening samples from potential participants for
- 7 the basis of Gilbert's Syndrome and eliminating or
- 8 including potential participants in a drug trial
- 9 in the knowledge of them possessing or not
- 10 possessing the genetic basis of Gilbert's
- 11 Syndrome.
- 12
- 13 2. Use of a test as claimed in claim 1 wherein the
- 14 method comprise the steps of:
- 15
- 16 a) taking a sample from each potential
- 17 participant in a drug trial,
- 18
- 19 b) screening the samples for the genetic basis
- 20 of Gilbert's Syndrome,
- 21
- 22 c) identifying participants having the genetic
- 23 basis of Gilbert's Syndrome, and
- 24
- 25 d) proceeding with drugs trials in the knowledge
- 26 of participants possessing or not possessing
- 27 the genetic basis of Gilbert's Syndrome.
- 28
- 29 3. Use of a test as claimed in claim 1 or 2 wherein
- 30 the sample is chosen from blood, buccal smear or
- 31 any other sample containing DNA from the potential
- 32 participants.
- 33
- 34 4. Use of a test as claimed in any of the preceding
- 35 claims further comprising the step of eliminating
- 36 participants having the genetic basis of Gilbert's

AMENDED SHEET

Act 34

25

- 1 Syndrome from a drugs trial.
2
3 5. Use of a test as claimed in any of claims 1 to 3
4 wherein the method comprises the further step of
5 selecting only participants having genetic basis
6 for Gilbert's Syndrome for a drugs trial.
7
8 6. Use of a test as claimed in any of claims 1 to 3
9 further comprising the step of interpreting the
10 results of the drugs trial in the knowledge that
11 certain participants have Gilbert's Syndrome.
12
13 7. Use of a test as claimed in any of the preceding
14 claims wherein the method comprises the steps of:
15
16 a) isolating DNA from each sample,
17
18 b) amplifying the DNA inner region indicating
19 the genetic basis for Gilbert's Syndrome,
20
21 c) isolating amplified DNA fragments, and
22
23 d) identifying individuals having the genetic
24 basis of Gilbert's Syndrome.
25
26 8. Use of a test as claimed in any of the preceding
27 claims wherein the DNA is amplified using the
28 polymerase chain reaction (PCR) using a
29 radioactively labelled pair of nucleotide primers.
30
31 9. Use of a test as claimed in any of claims 7 to 9
32 wherein the DNA region indicating the genetic
33 basis of Gilbert's Syndrome is the gene encoding
34 UDP-glucuronosyltransferase (UGT).
35
36 10. Use of a test as claimed in any of claims 7 to 10

AMENDED SHEET

Rule 126

00140000110000

Sub
D2

D2

Apr 13/89

26

1 wherein the DNA to be amplified is in an upstream
2 promoter region of the UGT 1*1 exon 1.

3
4 11. Use of a test as claimed in any of claims 7 to 11
5 wherein the DNA to be amplified includes the
6 regions between -35 and -55 nucleotides at the 5'
7 end of UGT 1*1 exon.

8
9 12. A kit for screening individuals participation in
10 drug trials, the kit comprising primers for
11 amplifying DNA in the region of the genome
12 indicating the genetic basis of Gilbert's
13 Syndrome.

14 13.
15 14. Primers for use of a test as claimed in any of the
16 preceding claims including primer pairs, AB or CD
17 as follows:

18 A/B (A, 5'-AAGTGAACCTCCCTGCTACCTT-3',
19 B, 5'-CCACTGGGATCAACAGTATCT-3') or
20 C/D (C, 5'-GTCACGTGACACAGTCAAAC-3';
21 D 5'-TTGCTCCTGCCAGAGTT-3').
22

Rule 126

03/11/2001 10:29

D2

Add D3

Add F1